Key Highlights
- Verrica Pharmaceuticals shares settled up 12% at $5.66.
- The company finished enrollment in COVE-2, its first Phase 3 pivotal study of YCANTH in common warts.
- Topline data is guided to Q1 2027.
- A second Phase 3 study, COVE-3, is past halfway and slated for mid-2027 data.
Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) shares settled up 12% at $5.66 after the company finished enrollment in COVE-2, the first Phase 3 pivotal study of YCANTH (cantharidin) in common warts.
What Happened
Topline data from COVE-2 is guided to Q1 2027. COVE-3, the second Phase 3 study, is past the halfway point and slated for mid-2027 data, which would support a supplemental filing if both studies succeed. YCANTH is already commercially available for molluscum, meaning this represents a label expansion opportunity rather than a new molecule.
Market Reaction
Shares rose as completing enrollment removed time-risk from the program, with common warts representing a large, underserved dermatology market for an already-approved formulation.
Outlook
Topline data from COVE-2, expected in Q1 2027, represents the next major catalyst, with COVE-3 data following in mid-2027 to potentially support a supplemental filing.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.